REATA PHARMACEUTICALS INC Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2014 to 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Reata Pharmaceuticals Inc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2014 to 2022.
- Reata Pharmaceuticals Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2023 was $193M.
- Reata Pharmaceuticals Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending June 30, 2023 was -$87.7M, a 71.2% increase year-over-year.
- Reata Pharmaceuticals Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$312M, a 4.73% decline from 2021.
- Reata Pharmaceuticals Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$298M, a 10.2% decline from 2020.
- Reata Pharmaceuticals Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$270M, a 6.87% increase from 2019.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)